Selank
NeuroprotectionCognitive performance and neurological recovery applications of Selank centre on its relationship to cerebral perfusion, BDNF and NGF signalling, and the gut-brain inflammatory axis. A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder. A 7-residue tuftsin-derived heptapeptide anxiolytic, Selank is investigated in nootropic, post-injury, and chronic-neuroinflammation contexts; the cognitive endpoints accumulate across 4-8 weeks rather than appearing acutely.
Key Takeaways
Cognitive lens: Selank acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Modulates GABA-A receptor systems indirectly. Neuro dose: 300 mcg per spray; 2-3 sprays daily daily for 2-4 week courses via intranasal/subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Semax + Selank Blend, DSIP.
Three pathways shape Selank's cognitive profile: Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Selank, with its Modulates GABA-A receptor systems indirectly Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The CNS effect lasts hours; plasma short pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Central nervous system access
Selank reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's intranasal/subq route(s) and CNS effect lasts hours; plasma short half-life set the timeline for CNS exposure. Modulates GABA-A receptor systems indirectly. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Receptor pharmacology and selectivity profile
Selank's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing Selank with peptides engaging the same primary receptor produces competition rather than synergy.
Where Selank is used for cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Post-TBI Recovery is one of the more-reported subjective benefits of Selank across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For bdnf support, Selank is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where Selank is used for mood stabilisation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300 mcg per spray; 2-3 sprays daily | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180 mcg per spray; 2-3 sprays daily | 4–6 weeks initial cycle |
| Neuroprotection focus | Intranasal | 300 mcg per spray; 2-3 sprays daily | Daily for 2-4 week courses |
| Maintenance phase | Intranasal | 210 mcg per spray; 2-3 sprays daily | Ongoing with periodic pauses |
Dose timing for Selank is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Selank stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Selank + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Selank's mechanism in cognitive / neurological protocols.
- Selank + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Selank's mechanism in cognitive / neurological protocols.
- Selank + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Selank's mechanism in cognitive / neurological protocols.
- Selank + LL-37: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Pairs naturally with Selank's mechanism in cognitive / neurological protocols.
Excellent. No reported dependence. Mild nasal irritation possible.
Lens-specific safety considerations for cognitive / neurological use of Selank: Excellent. No reported dependence. Mild nasal irritation possible. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Does Selank cross the blood-brain barrier?
Can Selank be stacked with other nootropics?
Best route for cognitive applications — injection or intranasal?
How long until I notice cognitive effects?
What is the regulatory status of Selank?
What class of compound is Selank?
Start a Selank Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Selank and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 751 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect lasts hours; plasma short
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Russian clinical trials in GAD
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Selank
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised